Madrigal Pharmaceuticals Inc. has announced a global licensing agreement with Suzhou Ribo Life Science Co. Ltd. to develop six preclinical small interfering RNA programs targeting metabolic dysfunction-associated steatohepatitis (MASH). The deal includes an upfront payment of $60 million to Ribo, with potential milestone payments up to $4.4 billion plus royalties. This agreement expands Madrigal’s pipeline beyond its approved MASH therapy, Rezdiffra, aiming to provide genetically targeted treatment approaches for the liver disease.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Madrigal Pharmaceuticals Signs Global siRNA Licensing Deal With Ribo
Madrigal Pharmaceuticals Inc. has announced a global licensing agreement with Suzhou Ribo Life Science Co. Ltd. to develop six preclinical small interfering RNA programs targeting metabolic dysfunction-associated steatohepatitis (MASH). The deal includes an upfront payment of $60 million to Ribo, with potential milestone payments up to $4.4 billion plus royalties. This agreement expands Madrigal’s pipeline beyond its approved MASH therapy, Rezdiffra, aiming to provide genetically targeted treatment approaches for the liver disease.